Literature DB >> 17960465

Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.

Yasushi Hashimoto1, Yoshiaki Murakami, Kenichiro Uemura, Yasuo Hayashidani, Takeshi Sudo, Hiroki Ohge, Emi Fukuda, Fumio Shimamoto, Taijiro Sueda, Eiso Hiyama.   

Abstract

Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has been increasingly identified as a precursor to infiltrating ductal adenocarcinoma. Telomerase activation in response to telomere crisis followed by telomere shortening is thought to be a crucial event in the development of most human cancers. The aim of this study was to determine when this event occurs in the context of histologically defined IPMN progression. We analyzed telomerase expression in 68 IPMN samples and assessed telomere length by quantitative fluorescence in situ hybridization in samples taken from 17 sequential IPMN patients that included 37 individual loci. Samples from pancreatic ductal adenocarcinomas (PDACs, n=15) and chronic pancreatitis patients (n=10) were also examined. Telomeres were significantly shortened in 36 (97.3%) of 37 IPMN loci, with average telomere length decreasing with IPMN progression. Notably, even adenoma IPMNs demonstrated a 50% reduction of telomere length in 7 of 14 foci examined. Marked telomere shortening was observed from the in situ IPMN carcinoma stage (P<0.001; vs borderline IPMNs) through the invasive stage, although telomerase had been activated, indicating that telomeres had shortened to a critical length by this histological grade. Up-regulated human telomerase reverse transcriptase expression was detectable and increased gradually with cancer development and was primarily observed at the borderline IPMN stage and then in more advanced histopathologies. Progressive telomere shortening predominantly occurs during early IPMNs carcinogenesis before telomerase activation and progression from borderline to carcinoma in situ IPMNs is the critical stage of IPMNs carcinogenesis at which telomere dysfunction occurs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17960465     DOI: 10.1007/s11605-007-0383-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  36 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

2.  Control of telomere length by the human telomeric protein TRF1.

Authors:  B van Steensel; T de Lange
Journal:  Nature       Date:  1997-02-20       Impact factor: 49.962

3.  Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Hiroki Ohge; Yasuo Hayashidani; Takeshi Sudo; Taijiro Sueda
Journal:  Surgery       Date:  2006-07-27       Impact factor: 3.982

4.  Telomere dysfunction provokes regional amplification and deletion in cancer genomes.

Authors:  Rónán C O'Hagan; Sandy Chang; Richard S Maser; Ramya Mohan; Steven E Artandi; Lynda Chin; Ronald A DePinho
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

5.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

6.  Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Norihiro Sato; Takashi Ueki; Noriyoshi Fukushima; Christine A Iacobuzio-Donahue; Charles J Yeo; John L Cameron; Ralph H Hruban; Michael Goggins
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

7.  Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb.

Authors:  K Hiyama; S Ishioka; Y Shirotani; K Inai; E Hiyama; I Murakami; T Isobe; T Inamizu; M Yamakido
Journal:  Oncogene       Date:  1995-03-02       Impact factor: 9.867

8.  Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.

Authors:  F Sessa; E Solcia; C Capella; M Bonato; A Scarpa; G Zamboni; N S Pellegata; G N Ranzani; F Rickaert; G Klöppel
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.

Authors:  Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

10.  High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma.

Authors:  E Hiyama; H Yamaoka; T Matsunaga; Y Hayashi; H Ando; S Suita; H Horie; M Kaneko; F Sasaki; K Hashizume; A Nakagawara; N Ohnuma; T Yokoyama
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

View more
  19 in total

1.  Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival.

Authors:  Tsuyoshi Hamada; Chen Yuan; Shuji Ogino; Brian M Wolpin; Ying Bao; Mingfeng Zhang; Natalia Khalaf; Ana Babic; Vicente Morales-Oyarvide; Barbara B Cochrane; J Michael Gaziano; Edward L Giovannucci; Peter Kraft; JoAnn E Manson; Kimmie Ng; Jonathan A Nowak; Thomas E Rohan; Howard D Sesso; Meir J Stampfer; Laufey T Amundadottir; Charles S Fuchs; Immaculata De Vivo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-19       Impact factor: 4.254

2.  Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas.

Authors:  Tatsuo Hata; Marco Dal Molin; Masaya Suenaga; Jun Yu; Meredith Pittman; Matthew Weiss; Marcia I Canto; Christopher Wolfgang; Anne Marie Lennon; Ralph H Hruban; Michael Goggins
Journal:  Clin Cancer Res       Date:  2016-05-26       Impact factor: 12.531

3.  Telomeres and cancer: from crisis to stability to crisis to stability.

Authors:  Peter J Campbell
Journal:  Cell       Date:  2012-02-17       Impact factor: 41.582

Review 4.  Leukocyte Telomere Length and Pancreatic Cancer Risk: Updated Epidemiologic Review.

Authors:  Samuel O Antwi; Gloria M Petersen
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

5.  Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid.

Authors:  Tatsuo Hata; Marco Dal Molin; Anne McGregor-Das; Tae Jun Song; Christopher Wolfgang; James R Eshleman; Ralph H Hruban; Michael Goggins
Journal:  J Mol Diagn       Date:  2017-12-08       Impact factor: 5.568

Review 6.  Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Marina Paini; Stefano Crippa; Stefano Partelli; Filippo Scopelliti; Domenico Tamburrino; Andrea Baldoni; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

Authors:  Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

8.  Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk.

Authors:  Samuel O Antwi; William R Bamlet; Kari G Rabe; Richard M Cawthon; Isoken Umudi; Brooke R Druliner; Hugues Sicotte; Ann L Oberg; Aminah Jatoi; Lisa A Boardman; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-20       Impact factor: 4.254

Review 9.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

10.  A prospective analysis of telomere length and pancreatic cancer in the alpha-tocopherol beta-carotene cancer (ATBC) prevention study.

Authors:  Shannon M Lynch; Jacqueline M Major; Richard Cawthon; Stephanie J Weinstein; Jarmo Virtamo; Qing Lan; Nathaniel Rothman; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Int J Cancer       Date:  2013-06-14       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.